Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising agent in selectively killing tumor cells. However, TRAIL monotherapy has not been successful as many cancer cells are resistant to TRAIL. Chemotherapeutic agents, such as doxorubicin have been shown to act synergistically with TRAIL, but the exact mechanisms of actions are poorly understood. In this study, we performed high-throughput small interfering RNA screening and genome-wide gene expression profiling on doxorubicintreated U1690 cells to explore novel mechanisms underlying doxorubicin-TRAIL synergy. The screening and expression profiling results were integrated and dihydroorotate dehydrogenase (DHODH) was identified as a potential candidate. DHODH is the rate-limiting enzyme in the pyrimidine synthesis pathway, and its expression was downregulated by doxorubicin. We demonstrated that silencing of DHODH or inhibition of DHODH activity by brequinar dramatically increased the sensitivity of U1690 cells to TRAIL-induced apoptosis both in 2D and 3D cultures, and was accompanied by downregulation of c-FLIP L as well as by mitochondrial depolarization. In addition, uridine, an end product of the pyrimidine synthesis pathway was able to rescue the sensitization effects initiated by both brequinar and doxorubicin. Furthermore, several other cancer cell lines, LNCaP, MCF-7 and HT-29 were also shown to be sensitized to TRAIL by brequinar. Taken together, our findings have identified a novel protein target and its inhibitor, brequinar, as a potential agent in TRAIL-based combinatorial cancer therapy and highlighted for the first time the importance of mitochondrial DHODH enzyme and pyrimidine pathway in mediating TRAIL sensitization in cancer cells.
INTRODUCTION
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily, and apoptosis is elicited upon binding to its death domain-containing transmembrane death receptors (DRs). Only the binding of TRAIL to DR4 or DR5 leads to the formation of death-inducing signaling complex consisting of the activated receptor, Fas-associated protein with death domain, and caspase-8/10. Activated caspase-8/10 proteolytically cleaves caspase-3 or the BCL-2 homology domain 3-interacting domain death agonist, resulting in the hallmarks of apoptosis. [1] [2] [3] TRAIL has over the years gained extensive interests as a therapeutic agent, because it kills preferentially tumor cells while sparing most of the normal cells intact, 4, 5 and can elicit the apoptotic program even in cells deficient in p53, which is required for successful conventional chemotherapy. 6 However, further studies have demonstrated that TRAIL monotherapy is not successful because a wide range of tumor cells are resistant to TRAIL treatment. [7] [8] [9] [10] [11] [12] Despite the discouraging findings, TRAIL remains to be an attractive therapeutic agent, because it is well tolerated and in conjunction with other anticancer modalities can improve the efficiency of therapy. To date, a variety of cytotoxic agents have shown synergy with TRAIL including DNA-damaging agents, HDAC inhibitors, proteasome inhibitors, and NF-kB and PI-3K pathway inhibitors. 13, 14 The molecular mechanisms resulting in the synergistic effects of the combinatorial treatment are not fully understood, although it has been demonstrated that some of these compounds are able to restore tumor cell sensitivity to TRAIL at the level of DRs/death-inducing signaling complex complex, mitochondria as well as several survival-signaling pathways. 15 In the current study, we aimed to explore novel mechanisms of action of doxorubicin in sensitizing resistant small cell lung cancer (SCLC) U1690 cells to TRAIL by using bioinformatic analysis that combines functional high-throughput small interfering RNA (siRNA) screening results with gene expression profiling. Our results showed that doxorubicin was able to downregulate the expression of dihydroorotate dehydrogenase (DHODH) and thereby sensitizing U1690 cells to TRAIL-mediated apoptosis. DHODH is the fourth and rate-limiting enzyme in the de novo biosynthesis of pyrimidines and is localized at the inner mitochondrial membrane. It functions to catalyze oxidation of dihydroorotate to orotate, that subsequently induces formation of uridine and cytidine nucleosides. 16 Pyrimidine is needed for RNA and DNA synthesis and thus is essential for cell proliferation and metabolism, making DHODH an attracting target for drug development in cancer, parasitic and immunological diseases. 17 Several DHODH inhibitors have been developed including brequinar, leflunomide and its active metabolite A77 1726 and teriflunomide. 18 Brequinar is an immunosuppressive and antiproliferative drug, which effectively functions to protect allograft and xenograft from rejections following transplantation, 19 and has been shown to inhibit the proliferation of T-cells, antibody production as well as tumor growth. 20 In our study, we found that the downregulation of DHODH expression either by siRNAs or doxorubicin or using its inhibitor brequinar significantly sensitized U1690 cells to TRAIL-mediated apoptosis. The induced apoptosis was accompanied by downregulation of c-FLIP L and significant effect on mitochondria. Addition of uridine abolished such sensitization effect signifying the importance of DHODH inhibition in TRAIL sensitization. Combinatorial treatment of TRAIL and brequinar also induced apoptosis in three dimensional (3D) organotypical cultures of U1690 cells. Furthermore, the ability of brequinar to enhance TRAIL-induced apoptosis was confirmed in several other cancer cell lines, but had no effect on human non-malignant mammary epithelial cells (HMECs). Taken together, we have provided evidence showing that inhibition of mitochondrial enzyme DHODH links metabolism of pyrimidines and TRAIL apoptotic signaling, suggesting utilization of DHODH inhibitors in TRAIL combinatorial therapy. These data revealed a new role of mitochondria in death-receptor-mediated cell death.
RESULTS
Gene expression profiling and high-throughput siRNA screening (HTS) of TRAIL-resistant U1690 cells reveal genes that contribute to doxorubicin-induced TRAIL sensitization In order to investigate the mechanistic underpinnings of cancer cell TRAIL resistance, U1690 SCLC cell line was selected as our cell model because it expresses death-inducing signaling complex components, including pro-caspase-8, Fas-associated protein with death domain, low-level surface DR5 but no detectable surface expression of DR4 9 and is resistant to TRAIL but can be sensitized by doxorubicin (Supplementary Figure 1) .
To evaluate how doxorubicin affects the overall gene expression, U1690 cells were treated with doxorubicin (1 mM) for 12 and 24 h and the genome-wide expression changes were analyzed. Genes with consistently up-or downregulated expression for more than 1.5-fold by doxorubicin are illustrated in Figure 1a (Supplementary Material and Methods). Approximately 80% of the genes with altered expression patterns from the 12 h time point were common to the 24 h time point (Figure 1b) . To facilitate further analysis, we averaged the expression values from both of the time points and a total of 1887 genes showed at least 1.5-fold changes in response to doxorubicin. The ingenuity pathway analysis (IPA) of these genes revealed several significantly altered To verify the importance of the observed gene expression changes in doxorubicin-TRAIL synergy, we performed a highthroughput siRNA screen in U1690 cells in the presence and absence of TRAIL. The siRNA library purchased from Qiagen (Hilden, Germany) targets the druggable genome, with 6951 genes that are known or putative to be responsive to smallmolecule drugs. Transfection efficiency of U1690 cells on 384-well plate format was confirmed showing that silencing of the key mitotic regulator PLK1 and the AllStars Cell Death siRNA control reduced the cell viability in comparison with the negative control by 43% and 93%, respectively (Supplementary Figure 2) . Four siRNAs were available for each gene and were pooled together into a single well to yield a final concentration of 50 nM. Cell viability was analyzed using CellTiter-Glo cell proliferation assay after the treatments. Statistical tools were applied for hit identifications, and are described in the Supplementary Material and Methods. An overview of normalized sensitization results is illustrated in Figure 1c . The screen was performed in two replicates and siRNAs targeting the known apoptosis pathway factors such as c-FLIP (CFLAR) and BIRC2 were found among the sensitization hits confirming the screens to be successful ( Figure 1c ). Altogether 288 reproducible sensitization hits were identified and marked in red (Figure 1c ). The detailed list of the 288 genes is presented in the Supplementary File 2. The IPA analysis results for major cell functions, pathways and networks of the 288 TRAIL sensitization hits are presented in Supplementary File 3.
Next, we integrated the siRNA-screening data with the doxorubicin-treated gene expression profiles to gain an overview of genes that have a potential role in doxorubicin sensitization in U1690 cells. A hit was defined if it was both a TRAIL sensitization hit and its expression was downregulated by at least 1.5-fold by doxorubicin treatment. The integration resulted in 22 genes ranging from transcription factors to nuclear transporters to various enzymes (Figure 1d , red spots and Table 1 ). A detailed representation of results from the entire druggable genome screen with raw and normalized values as well as integration of the gene expression data with fold changes can be found in Supplementary File 4, from which TRAIL sensitization scores, doxorubicin-induced expression fold changes as well as the hit lists can be filtered out. Based on the literature, only one gene, importin b1 (KPNB1), out of the 22 identified has been shown to be involved in TRAIL-mediated signaling, 21 proving that our approach is able to generate true and novel hits. To further narrow down genes to be validated in the following studies, we analyzed these 22 genes using the IPA program to explore whether there were known inhibitors available, because existing small molecule compounds exhibit advantageous properties in therapeutics over siRNAs, which still have limited in vivo applications. 22 The IPA revealed that only 2 out of 22 genes had known inhibitors available, with one of them being DHODH (Table 1 ). Due to the importance of DHODH and its inhibitors in the clinics, we continued our validation studies on this particular gene.
Silencing of DHODH sensitizes U1690 cells to TRAIL To verify the observed sensitization effects of DHODH from the siRNA screening, we selected two individual siRNAs targeting DHODH and monitored their effects on both cell viability and apoptosis in the presence and absence of TRAIL. U1690 cells were transfected with the siRNAs for 48 h followed by TRAIL addition (100 ng/ml, 24 h). In the presence of TRAIL, silencing of DHODH by both siRNAs reduced the cell proliferation ( Figure 2a ) and increased caspase-3/7-like activities (Figure 2b ). The silencing ability of the siRNAs was verified by qRT-PCR (Figure 2c ).
DHODH inhibitor brequinar enhances TRAIL-induced apoptosis in U1690 cells
Next, we wanted to examine whether DHODH inhibitors could be utilized in synergizing TRAIL activity. U1690 cells were treated with 100 mM of leflunomide, its metabolite A77 1726 and brequinar for 2 h before treatment with different concentrations of TRAIL, and Abbreviation: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
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cell viability was measured 24 h afterwards ( Figure 3a ). Both leflunomide and A77 1726 were able to induce more pronounced cell death in the absence of TRAIL comparing with brequinar, but had no effect to potentiate TRAIL-induced cell death. However, brequinar, as a single agent, did not affect significantly on cell viability but when treated sequentially with TRAIL, cell death was dramatically increased. Therefore, brequinar was selected in the following studies. The concentration dependence of brequinar on TRAIL-induced apoptosis was assessed by treating U1690 cells with three brequinar concentrations in combination with increasing doses of TRAIL for 24 h and apoptosis was measured by caspase-3/7 activation. Already at 10 mM, brequinar was able to enhance TRAILinduced caspase activation, while 100 mM exhibited the highest synergistic effect with 50 ng/ml TRAIL. Higher concentrations of TRAIL did not result in additional synergy (Figure 3b ). Furthermore, PARP cleavage was also observed in response to brequinar and TRAIL treatment (Figure 3c ), indicating the occurrence of apoptosis.
To examine the molecular mechanisms involving in the TRAIL signaling pathway, U1690 cells were pretreated with brequinar (100 mM, 2 h) with the following TRAIL treatment (100 ng/ml, 24 h) and immunoblots were performed. Treatment with brequinar caused a significant downregulation in protein levels of c-FLIP L , which was further decreased after addition of TRAIL (Figure 4a) . Similar c-FLIP L downregulation was observed when U1690 cells were transfected with siRNAs against DHODH and treated with TRAIL ( Figure 4a) . However, the level of c-FLIP S was not changed in response to brequinar. Furthermore, such reduction of c-FLIP L was accompanied by processing of procaspase-8 ( Figure 4a ). Activation of caspase-8 was also confirmed by caspase-8 activity assay ( Figure 4b ). As DHODH is a mitochondrial enzyme, we decided to explore the effect of brequinar on mitochondrial membrane potential using TMRE staining. Although treatment with brequinar by itself did not cause any significant effect on mitochondria, the combining treatment with brequinar and TRAIL dramatically increased the number of cells with drop of mitochondrial membrane potential, suggesting that inhibition of DHODH also facilitates TRAIL-mediated apoptosis at the level of mitochondria (Figure 4c) . Furthermore, based on the previous report that doxorubicin increases the expression of DR5, 9 we evaluated the expression of DR5 upon brequinar treatment. U1690 cells were either untreated or treated with brequinar (100 mM, 24h) or doxorubicin (1 mM, 24 h) and the total level of DR5 expression (Figure 5a ), and surface expression of DR4 and 5 (Figures 5b and c) were examined by immunoblots and flow cytometry. As brequinar had its own green fluorescence, all the histograms of brequinartreated samples were shifted to the right. The MFI values were normalized according with level of brequinar's autofluorescence in green channel. Relative normalized surface DR expression is presented in Figure 5c . These data indicated that in contrast to doxorubicin, inhibition of DHODH with brequinar had no impact on the expression of DR4 and DR5 receptors. Taken together, inhibition of DHODH by brequinar sensitized cells to TRAILmediated apoptosis by reducing the level of c-FLIP L , and such a response was also accompanied by the effect on mitochondria.
Uridine rescues brequinar-TRAIL-induced apoptosis As DHODH is a key enzyme in the de novo synthesis of uridine monophosphate, which is pivotal for many cellular functions, we examined whether uridine could rescue the TRAIL sensitization Figure 2 . Silencing of DHODH sensitizes U1690 cells to TRAIL. (a) U1690 cells were transiently transfected with two different siRNAs against DHODH, and 48 h post transfection, TRAIL (100 ng/ml) was added to the cells. The cells were further incubated for 24 h and cell viability was measured using CellTiter-Glo Luminescence Assay. (b) Same as in (a), and apoptosis was measured using Caspase-Glo 3/7 Assay. (c) Taqman quantitative real-time PCR after DHODH silencing. U1690 cells were transfected with siDHODH (13 nM) or negative control siRNA for 48 h. Total RNA was isolated and analyzed using actin (ACTB) as a reference. The results (a-c) were averages of three replicates and were representative of three biological repeats (Student's t-test; *Po0.05, **Po0.01, ***Po0.001). RLU: relative luminescence units.
effect induced by brequinar in U1690 cells. We incubated U1690 cells with increasing concentrations of brequinar with or without uridine (100 mM, 2 h) followed by 24 h incubation with or without TRAIL (50 ng/ml). Apoptosis was detected by caspase-3/7 activation as shown in Figure 6a . Uridine alone did not affect the cell viability, whereas it completely reversed apoptosis induced by combined treatment of brequinar (10 and 50 mM) and TRAIL. At 100 mM of brequinar, the reverse effect by uridine was attenuated to 25%. Immunoblots in Figure 6b also showed that both PARP and caspase-3 cleavages enhanced by brequinar and TRAIL were rescued by uridine with significant less cleavages of PARP and caspase-3 at 10 mM of brequinar. The rescue effect was, however, less obvious at 100 mM of brequinar. These results suggested that uridine production was important for U1690 cells to maintain its resistance to TRAIL and reduction of uridine levels by inhibition of DHODH by brequinar at lower concentrations sensitized cells to TRAIL.
Doxorubicin reduces DHODH expression and uridine reverses doxorubicin sensitization effect at lower concentrations The gene expression profiling data showed that expression of a variety of genes, including DHODH, was modulated by doxorubicin treatment. Therefore, we hypothesized that doxorubicin might pursue the sensitization effect via the DHODH pathway. The gene expression profiling data were verified as both DHODH mRNA and protein expression decreased in response to increasing doses of doxorubicin (Figure 7a ). To further validate the importance of the DHODH pathway in the doxorubicin-TRAIL synergy, we treated U1690 cells with 0.1 and 1 mM of doxorubicin in the presence and absence of TRAIL and/or uridine. As shown in Figure 7b , apoptosis induced by 0.1 mM doxorubicin and 50 ng/ml TRAIL was diminished by uridine by 25%, whereas uridine was not able to reverse the sensitization effect induced by 1 mM of doxorubicin. These data indicated that inhibition of DHODH has, at least in part, an important role in the sensitization of doxorubicin to TRAIL. Thus, we revealed that downregulation of DHODH induced by doxorubicin is among the mechanisms that contribute to the sensitization of cancer cells to TRAIL-mediated apoptosis.
Brequinar sensitizes multiple cancer cell lines to TRAIL and induces apoptosis of U1690 cells in 3D cell culture upon TRAIL treatment The results that have been shown were performed on SCLC U1690 cells. To examine whether the effects observed using brequinar was also true in other cancer cell models, we employed three different cancer cell lines, LNCaP (prostate cancer), MCF-7 (breast cancer) and HT-29 (colon cancer) cells. These cells were pretreated with brequinar (50 mM, 2 h) before incubation with TRAIL (50 ng/ml, 24 h). Apoptosis induction was measured by caspase-3/7 activity assay. As shown in Figure 8a , brequinar was able to elevate the apoptosis induction in LNCaP, MCF-7 and HT-29 cells to 1.9-, 1.2-and 1.8-folds, respectively. These results implied that brequinar may be used as a drug in TRAIL combinatorial treatment on various cancer types. To examine whether the brequinar and TRAIL treatment can be tolerated by non-cancerous tissues, HMECs were employed. In contrary to cancer cell lines, HMECs did not show any sensitization to TRAIL when pretreated with brequinar (50 mM, 2 h) indicating possible cancer-specific property of the combinatorial treatment (Figure 8a ). ) and subsequently treated with TRAIL (100 ng/ml, 24 h). The expression of c-FLIPs and processing of caspase-8 was analyzed by immunoblot. GAPDH was used as a loading control. U1690 cells were transfected with siDHODH and treated with 100 ng/ml of TRAIL as described in Figure 2 . After the incubation period, cells were lysed and subjected to SDS-PAGE, transferred onto membranes and blotted with antibodies against c-FLIP or actin. (b) U1690 cells were pretreated with brequinar (10, 50 or 100 mM, 2 h) and the cells were subsequently treated with 50 ng/ml of TRAIL for additional 24 h. Caspase-8 activity was measured using Caspase-Glo 8 Assay. The results were averages of three replicates and were representative of three biological repeats (Student's t-test; **Po0.01). (c) U1690 cells were untreated, treated with TRAIL (100 ng/ml, 24 h) alone or pretreated with brequinar (100 mM, 2 h) and subsequently treated with TRAIL (100 ng/ml, 24 h). Mitochondrial membrane potential (MMP) was assessed using TMRE staining. 
To further characterize the response of cancer cells to brequinar and TRAIL towards an in vivo setting, we performed miniaturized 3D cell culture of U1690 cells. Five days post culturing on matrigel, U1690 cells generated large and irregular spheroids (Figure 8b ), which were later subjected to treatments with brequinar and TRAIL. Cell morphology and apoptosis induction were measured by microscopy and caspase activity assay. As single agents, brequinar and TRAIL had minor effects on the morphology of U1690 spheres, whereas the combination treatment induced spheroidal changes such as membrane blebbing and structure rupture (Figure 8b) . Quantification of the overall apoptosis induction using caspase-3/7 activity assay confirmed that the combined treatment induced an increase of caspase-3/7 activity in U1690 spheroids (Figure 8c ). These results suggested that combination therapy of TRAIL and brequinar can also be effective on 3D organotypic cultures of U1690 cells and may be utilized as an initial evidence of using brequinar and TRAIL towards an in vivo validation.
DISCUSSION
Previous studies have shown that the chemotherapeutic drug doxorubicin overcomes the TRAIL resistance and acts synergistically with TRAIL to induce more dramatic cancer cell death. 15 Although modulation of surface DR levels and localization as well as downregulation of anti-apoptotic genes, such as c-FLIP S/L and X-IAP, have been implicated to contribute to the sensitization of doxorubicin to TRAIL in cancer cells, 15 the exact molecular mechanism underlying the synergistic effect is not well defined. Our study explored pertinent contributory mechanism of doxorubicin in sensitizing resistance cells to TRAIL. Understanding of these mechanisms could provide the possibility to identify novel drugs for combining with TRAIL for cancer treatment.
In this regard, a genome-wide gene expression profiling of doxorubicin-treated SCLC U1690 cells was performed and the importance of the genes with altered expression was accessed by a synthetic lethal siRNA high-throughput screen. HTS has been utilized in searching for novel factors in mediating TRAIL resistance [23] [24] [25] and HTS format of compound screening has also been widely employed to identify synergistic TRAIL sensitizers. [26] [27] [28] In our study, we integrated the genome-wide gene expression profiles with the siRNA screening data to explore mechanisms of actions of doxorubicin in sensitizing resistant cells to TRAIL. The integration identified 22 genes to be both downregulated by doxorubicin treatment and to induce U1690 cells TRAIL sensitivity upon expression silencing. With the exception of KPNB1, all other 21 genes have not been linked to TRAIL signaling previously. Thus, our findings provided novel insights to inspire new mechanistic studies of TRAIL therapy in SCLC.
DHODH is an important mediator in the pyrimidine pathway and as DHODH inhibitors are readily available, we continued the validation procedure focusing on DHODH. Here we showed that DHODH has an important role in sensitizing SCLC U1690 cells to TRAIL-induced apoptosis, and highlighted an essential role of mitochondria. Silencing of DHODH using siRNAs in conjunction with TRAIL treatment dramatically reduced cell proliferation and Figure 6 . Uridine rescues apoptosis induced by brequinar and TRAIL combinatorial treatment. (a) U1690 cells were pretreated with brequinar (10, 50 or 100 mM) either alone or together with 100 mM uridine for 2 h. Subsequently, the cells were treated with 50 ng/ml of TRAIL for 24 h. Caspase-3/7 activity was measured using Caspase-Glo 3/7 Assay. The results were averages of three replicates and were representative of three biological repeats (Student's t-test; **Po0.01, ***Po0.001). (b) U1690 cells were pretreated with 10 or 100 mM of brequinar with or without 100 mM uridine and the cells were subsequently treated with TRAIL (50 ng/ml, 24 h). After the incubation period, cells were lysed and subjected with SDS-PAGE, transferred to membranes, and blotted with antibodies against PARP, cleaved caspase-3 or actin.
induced apoptosis. Doxorubicin significantly reduced both protein and mRNA expression of DHODH in U1690 cells in a concentration-dependent manner. Interestingly, uridine, which is the most abundantly available salvageable pyrimidine nucleoside in vivo, was able to reverse the sensitization effect mediated by doxorubicin at a lower concentration. These results pinpointed to a potential role of DHODH in mediating TRAIL resistance in a subset of cancer cell lines. The importance of pyrimidine pathway has become evident as serious diseases such as hereditary orotic aciduria, anemia and neurological disorders have been linked to defects in the pyrimidine metabolism. 17 However, knowledge on whether pyrimidine pathway and metabolism could be involved in TRAIL signaling is relatively scarce with one report showing that TRAIL-induced apoptosis in HT-20 cells was inhibited by glutamine via the pyrimidine pathway. 29 Our finding suggested that DHODH involved pyrimidine pathway may contribute to TRAIL signaling and doxorubicin exerts its TRAIL sensitization effect via the DHODH pyrimidine pathway. We cannot, however, rule out the fact that other mechanisms, such as upregulation of DR5 9 as well as the B1900 gene expression changes induced by doxorubicin, contribute to the effect of sensitization, and we suggest that the DHODH pyrimidine pathway is among the multiple mechanisms that cells select to respond to doxorubicin.
To date, a number of DHODH inhibitors have been classified, and they have proven efficacy for treatment of cancer 30 and immunological disorders, such as rheumatoid arthritis and multiple sclerosis. 31 Here, we investigated the role of DHODH inhibitors in sensitizing U1690 cells to TRAIL. Synergy between TRAIL and other chemotherapeutic drugs in SCLC cells has only been shown with etoposide, 9 DNA methyltransferase and histone deacetylase 32 in addition to doxorubicin. In this study, we showed that DHODH inhibitor brequinar could also be utilized as a TRAIL sensitizer. The other two inhibitors, leflunomide and its active metabolite A771726 did not sensitize cells to TRAIL, and in fact they were cytotoxic to cells as single agents. These data coincided with previous findings showing that leflunomide and A77 1726 could be used in inducing apoptosis in melanoma and multiple myeloma cells. [33] [34] [35] In one previous report, A77 1726 was shown to enhance TRAIL-induced apoptosis in human hepatic stellate cells and thereby function in anti-fibrotic therapy. 36 These data suggested that the differences in structures, cell line origin as well as molecular mechanism of actions of these DHODH inhibitors 18 might contribute to these distinct effects.
Brequinar was clinically developed due to its anti-tumor activity, and its effect on various cancer cell lines has previously been shown, being more potent in half of the cell lines tested and less potent in the other half. 37 However, the use of brequinar in clinical trials for cancer treatment has been limited. When advanced lung cancer patients (including both NSCLC and SCLC patients) were treated using brequinar, insufficient killing of tumor cells was observed. 38 We also observed that brequinar possessed significant lower toxicity towards U1690 cells and in fact this characteristic would be optimal for a combinatorial therapy. We demonstrated that pretreatment with brequinar dramatically enhanced the susceptibility of U1690 cells to TRAIL-induced apoptosis, and the observed TRAIL resistance could already be overcome by a combination of brequinar and TRAIL. These observations were further confirmed in 3D cell culture of U1690 cells. The induced apoptosis was accompanied with activation of caspase-8 and mitochondrial depolarization. Inhibition of DHODH by either brequinar or siRNAs reduced expression of c-FLIP L but had no 1 mM) either alone or together with 100 mM uridine for 2 h. Subsequently, the cells were treated with 50 ng/ml of TRAIL for 24 h. Caspase-3/7 activity was measured using Caspase-Glo 3/7 Assay. The results were averages of three replicates and were representative of three biological repeats (Student's t-test; **Po0.01).
effects on c-FLIP S . Short and long FLIPs have differential regulatory roles in apoptosis and small molecule therapy selectively targeting FLIP variants have been used in sensitizing cancer cell lines to TRAIL. 39 We have not studied whether the observed downregulation of c-FLIP L undergoes via transcriptional or translational pathways, but our data demonstrated that reduction of FLIP level is important in sensitizing U1690 cells to TRAIL by brequinar. Moreover, it has been shown that expression of surface DR5, but not DR4, was significantly enhanced due to doxorubicin treatment in SCLC cells. 9 However, in contrast to doxorubicin, (a) LNCaP, MCF-7, HT-29 and HMECs were pretreated with 50 mM brequinar for 2 h and the cells were subsequently treated with 50 ng/ml of TRAIL for an additional 24 h. Caspase-3/7 activity was measured using Caspase-Glo 3/7 Assay. The results were averages of three replicates and were representative of three biological repeats (Student's t-test; **Po0.01, ***Po0.001). (b) Live cell imaging of U1690 spheres which were pretreated with 50 or 100 mM brequinar for 2 h followed by 50 or 100 ng/ml of TRAIL for an additional 48 h. (c) Same as in (b), and caspase-3/7 activity of U1690 spheroids treated was measured using Caspase-Glo 3/7 Assay (Student's t-test; *Po0.05, **Po0.01).
Dihydroorotate dehydrogenase inhibition sensitizes cells to TRAIL T He et al which also by itself downregulated DHODH expression, brequinar had no effect on the total or surface expression of DR5. Another DHODH inhibitor, leflunomide, was also observed not to have any impact on DR4 and DR5 expression in human hepatic stellate cells, 36 indicating that brequinar and leflunomide could preferentially depend on other mechanisms, such as downregulating FLIPs and inhibiting the pyrimidine pathway to accelerate the TRAIL-induced apoptosis. The sensitization effect was reversed at lower concentrations of brequinar by the addition of uridine. These results further confirmed that DHODH expression and activity indeed contributed to the TRAIL resistance in U1690 cells. However, the rescue effect of uridine was less prominent with higher concentrations of brequinar, indicating additional mechanisms are likely activated. Furthermore, the brequinar TRAIL synergy was also found in other cancer cell lines, LNCaP, MCF-7 and HT-29 cells. Numerous compounds have been reported to synergistically act with TRAIL to potentiate apoptosis in these cells, including chemotherapeutic drugs and natural compounds. [40] [41] [42] [43] [44] [45] Our results added the usage of brequinar into this continuously growing list of agents that can be utilized in TRAIL combinatorial therapy. Interestingly, the combined treatment of brequinar and TRAIL did not harm the mammary epithelial cells HMEC suggesting normal cells possess own mechanisms to overcome the sensitization effect.
In conclusion, we analyzed novel mechanisms of action of doxorubicin in TRAIL sensitization and identified a key role for the mitochondrial enzyme DHODH and the pyrimidine synthesis pathway. We also characterized DHODH inhibitor brequinar as a potential TRAIL sensitizer. Although brequinar as a single agent has limited therapeutic windows, it may serve as a senstitizer for TRAIL in combinatorial cancer therapy. Similar approach could also be utilized in evaluating mechanisms of other existing or potential anti-cancer agents and thereby provide novel directions for development of combinatorial cancer therapy.
MATERIALS AND METHODS
Cell culture and reagents U1690, LNCaP, MCF-7 and HT29 cells (ATCC, Manassas, VA, USA) were cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine and 1% penicillin/streptomycin. HMECs (ATCC) were cultured 1:1 in DMEM (4500 mg/l glucose, Sigma-Aldrich, St Louis, MO, USA)/Ham's F12 (Gibco/Invitrogen) supplemented with 1% FBS, 2 mM L-glutamine, 10 mg/ml insulin, 0.5 mg/ml hydrocortisone, 0.05 mg/ml choleratoxin and 0.01 mg/ml EGF (all from Sigma-Aldrich). Doxorubicin, brequinar, leflunomide and uridine were from Sigma-Aldrich, and A77 1726 was from Enzo Life Sciences (Farmingdale, NY, USA). Recombinant human TRAIL/TNFSF10 was obtained from R&D Systems (Minneapolis, MN, USA). DHODH siRNAs and AllStars Negative and Cell Death Control siRNAs were purchased from Qiagen.
High-throughput siRNA screening
The siRNA library targeting human druggable genome (Qiagen GmbH) consists of four siRNAs per gene. These four siRNAs were pooled into the same well (final assay concentration 50 nM) on 384-well white, clearbottom assay plates (Greiner Bio-One GmbH, Frickenhausen, Germany), followed by addition of siLentFect (Bio-Rad Laboratories, Hercules, CA, USA) using a Multidrop 384 Microplate Dispenser (Thermo Fisher Scientific Inc, Waltham, MA, USA) for 1 h at room temperature. Cell suspension was thereafter overlaid and the plates were incubated for 48 h at þ 37 1C. Recombinant human TRAIL with a final concentration of 100 ng/ml was subsequently added to plates designated for TRAIL treatment and they were further incubated for 24 h at þ 37 1C.
Illumina gene expression
Gene expression profiles of U1690 cells treated with or without 1 mM doxorubicin for 12 and 24 h were analyzed with two replicates. Total RNA was extracted using RNeasy (Qiagen GmbH) according to the manufacturer's protocol. Integrity of the RNA before hybridization was monitored using a Bioanalyzer 2100 (Agilent, Santa Clara, CA, USA) according to manufacturer's instructions. Purified total RNA (500 ng) was amplified with the TotalPrep Kit (Ambion, Austin, TX, USA) and the biotin labeled cRNA was hybridized to Sentrix HumanRef-8 Expression BeadChips (Illumina, San Diego, CA, USA). The assay was performed at the Finnish DNA Microarray Centre, Turku Centre for Biotechnology. The arrays were scanned with the BeadArray Reader (Illumina) and the raw data were obtained by GenomeStudio (Illumina). The microarray data are accessible at the NCBI's Gene Expression Omnibus through a GEO Series accession number (GSE42531).
Transient transfections U1690 cells were reverse-transfected using SilentFect (Bio-Rad Laboratories) with siRNAs against DHODH 13 nM, (Qiagen, SI00363391, SI00363398) on 384-well plates for 48 h and treated with 100 ng/ml TRAIL for 24 h post-transfection.
Cell viability and caspase activity assays Viability or caspase-3/7/8 activities was measured using CellTiter-Glo Luminescence Assay (Promega, Madison, WI, USA) or Caspase-Glo 3/7 Assay (Promega) or Caspase-Glo 8 Assay (Promega) with Envision Platereader according to manufacturer's instructions.
Surface TRAIL receptor expression. 
Immunoblotting
Cells were lysed and separated on SDS-polyacrylamide gels and western blotting was performed using antibodies against cleaved caspase-3 (Asp175) (9661, Cell Signaling Technology, Danvers, MA, USA), PARP (P248, Sigma-Aldrich), DHODH (WH0001723M1, Sigma-Aldrich) DR5 (D3938, Sigma-Aldrich), GAPDH (2275-PC-100, Trevigen, Gaithersburg, MD, USA), actin (A1978 Sigma-Aldrich), caspase-8 and c-FLIP (kindly provided by Drs I Lavrik and P Krammer) antibodies. Secondary antibodies coupled to horseradish peroxidase were from Amersham Biosciences (Freiburg, Germany), and visualization was performed using enhanced chemiluminescence procedure (Amersham Biosciences).
Real-time quantitative PCR analysis U1690 cells were reverse transfected with two different siRNAs against DHODH (Qiagen, SI00363391, SI00363398) for 48 h or treated with doxorubicin (0.2, 0.5 and 1 mM) for 24 h on 48-well plates. RNA samples were extracted using RNeasy Mini Kit (Qiagen) and reverse transcribed to cDNA (High Capacity cDNA Reverse Transcription Kit, Applied Biosystems, Foster City, CA, USA). Taqman quantitative real-time PCR was performed using ABI Prism 7900 (Applied Biosystems) with specific primers for DHODH (For 5 0 -CGGAGCCTTCAGGGAAAG-3 0 , Rev 5 0 -CACTCTCCGCAAGCC ATCC-3 0 ) and b-actin (ACTB) from the Universal Probe Library (Roche Applied Biosciences, Basel, Switzerland). The results were analyzed using SDS 2.3 and RQ manager software (Applied Biosystems). ACTB was used as an endogenous control to determine the expression of DHODH by relative quantitation method. Averaged data were obtained from three biological experiments with quadruplicates.
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Miniaturized 3D cell cultures and morphological image and apoptosis analysis U1690 cells were plated on miniaturized 3D cultures as described earlier. 46 Cells were seeded with defined numbers (1500 cells/well). After 5 days, spheroids formed were pretreated with brequinar for 2 h and subsequent TRAIL treatment for 48 h. The time lapse phase-contrast multicellular structures images were acquired by Incucyte (Essen Instruments, Ann Arbor, MI, USA) and caspase-3/7 activity was measured using Caspase-Glo 3/7 Assay (Promega).
